|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 9,604,901
Executive Summary
U.S. Patent 9,604,901, issued on March 28, 2017, to Novartis AG, pertains to a novel class of compounds for the treatment of diseases related to the epidermal growth factor receptor-tyrosine kinase (EGFR-TK), notably non-small cell lung cancers (NSCLCs). This patent claims exclusive rights to specific quinazoline derivatives with kinase inhibitory activity, emphasizing compositions, methods of synthesis, and their therapeutic applications.
This report provides a comprehensive analysis of the patent's scope and claims, evaluates its position within the patent landscape of EGFR inhibitors, and highlights strategic considerations for stakeholders.
1. Background and Context
1.1. Therapeutic Area
- Focused on targeted cancer therapies, specifically EGFR-TK inhibitors.
- Key for NSCLC, resistance mechanisms, and overcoming prior-generation limitations.
1.2. Patent Timeline
| Patent Number |
Filing Date |
Issue Date |
Priority Date |
Assignee |
| 9,604,901 |
August 29, 2014 |
March 28, 2017 |
August 29, 2013 |
Novartis AG |
1.3. Related Patents and Competitors
- Pfizer's gefitinib (AZD9291/TMisolid)
- AstraZeneca's osimertinib (Tagrisso)
- Others: Patent families covering various EGFR inhibitor classes, such as quinazolines, pyrimidines, etc.
2. Scope and Claims of U.S. Patent 9,604,901
2.1. Summary of Patent Claims
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
15 |
Cover specific quinazoline derivatives, their compositions, and methods of use. |
| Dependent Claims |
25 |
Narrowed versions, specific substituents, synthesis methods, or formulations. |
2.2. Key Elements of the Independent Claims
| Element |
Description |
Example from Claim 1 |
| Chemical Core |
Quinazoline or fused quinazoline scaffold |
"A compound comprising a quinazoline ring..." |
| Substituents |
Defined at positions R1, R2, R3, etc., with specific chemical groups |
"wherein R1 is selected from the group consisting of..." |
| Pharmacological Activity |
Kinase inhibitory activity, especially EGFR inhibition |
"that exhibits inhibitory activity against EGFR kinase..." |
| Therapeutic Use |
Treatment of EGFR-mutant cancers, especially NSCLC |
"use of the compound in the treatment of non-small cell lung cancer." |
| Synthesis Method |
Specific chemical synthesis steps for making the compounds |
Included in dependent claims, not in independent claims. |
2.3. Notable Claim Features
- Focus on small molecules with specific substitutions to enhance selectivity and potency.
- Emphasis on selectivity for mutant versus wild-type EGFR.
- Claims encompass both the compounds themselves and their pharmaceutical compositions.
2.4. Claim Limitations
- Specificity of substituents at R positions.
- Limited to compounds with certain chemical moieties.
- Use cases primarily in NSCLC therapy.
3. Patent Landscape for EGFR-Inhibiting Compounds
3.1. Overlapping Patent Families
| Patent Family |
Owner |
Key Features |
Filing/Issue Dates |
Scope |
Geographic Coverage |
| AstraZeneca |
AstraZeneca |
Osimertinib → Third-generation EGFR inhibitor targeting T790M mutations |
2012-2014 |
Specific to third-gen inhibitors |
Global, including US, EU, JP |
| Pfizer |
Pfizer |
Gefitinib / AZD9291 |
1991-2000, 2013 |
First- and third-generation inhibitors |
US, EU, JP |
| Clovis Oncology |
Clovis |
Rucaparib (PARP inhibitor) — Different class but overlapping lung cancer indications |
2000-2012 |
Alternative pathways |
Global |
3.2. Key Patent Holders and Their Strategies
| Company |
Patent Concentration |
Focus Area |
Notable Patents |
| Novartis |
Broad quinazoline derivatives |
EGFR and other kinase inhibitors |
9,604,901; others in family |
| AstraZeneca |
Third-generation inhibitors, T790M mutants |
Osimertinib |
Several originating from 2012+ |
| Genentech/Roche |
Different kinase inhibitors targeting EGFR |
Multiple patent families |
Various |
3.3. Patent Cilia and Challenges
- Patent Thickets: Dense patent filings around chemical structures and specific mutations.
- Validity Challenges: Due to prior art, obviousness rejections, especially in broad compound claims.
- Litigation & Free-Use: Several patents face legal disputes, especially concerning generic manufacturing timelines.
4. Analysis of Rights and Limitations
4.1. Composition Claims
- Protected compounds with specific substitutions enhancing selectivity.
- Limited to quinazoline derivatives with particular side chains.
4.2. Method of Use Claims
- Methods for diagnosing EGFR mutations.
- Treatment methods involving administering the compounds.
4.3. Synthesis and Formulation Claims
- Illustrations of chemical synthesis routes.
- Pharmaceutical formulations with the compounds.
4.4. Geographic and Patent Term Considerations
- US patent offers protection until approximately 2034, considering patent term adjustments.
- Similar patents might expire earlier in other jurisdictions.
5. Strategic Insights for Stakeholders
| Stakeholder |
Opportunities |
Risks |
| Pharmaceutical Innovators |
Patent claims covering novel quinazoline derivatives can serve as lead compounds for further drug development |
Risk of patent invalidation due to prior art or obviousness |
| Generic Manufacturers |
Potential to design around specific claims; challenge patent validity |
Patent infringement litigation, market exclusivity loss |
| Legal/Regulatory |
Monitor patent scope for licensing/regulatory approval pathways |
Challenges concerning patent scope limitations and prior art invalidation |
6. Deep Dive: Comparative Analysis of Scope
| Feature |
U.S. Patent 9,604,901 |
Other Notable Patents (e.g., AstraZeneca’s osimeritinib, Pfizer's gefitinib) |
Comments |
| Chemical Core |
Quinazoline derivatives |
Broad kinase inhibitor classes |
Focused on select compounds |
| Mutant Selectivity |
Emphasized R-specific substitutions |
Target-specific mutations (T790M), some broad-spectrum |
The patent emphasizes mutations, similar to competitors |
| Method Claims |
Includes synthesis and use |
Use in treatment, combinations |
The scope partly overlaps with others’ claims |
| Coverage of Resistance Mutations |
Explicitly claims mutants |
Same |
Resistance-driven claims are common in this space |
7. FAQs
Q1: How does U.S. Patent 9,604,901 compare to other EGFR inhibitor patents?
It claims specific quinazoline derivatives with particular substituents designed for enhanced mutant selectivity. While similar to other patents in targeting NSCLC, its chemical scope is narrower than broad kinase class patents, focusing on particular substituents.
Q2: Can this patent be challenged based on prior art?
Yes. Many quinazoline compounds and methods are documented historically. A valid challenge could target the novelty or non-obviousness of specific substituents or synthesis methods.
Q3: What is the patent’s coverage in international markets?
While focused on the US, applicants likely filed corresponding applications under the Patent Cooperation Treaty (PCT) and regional statutes, aspiring for broader protection.
Q4: Are method-of-use claims enforceable?
Yes, method claims for therapeutic applications are generally enforceable but may face challenges if prior art demonstrates similar methods.
Q5: How does the patent landscape influence drug development strategies?
It encourages designing structurally distinct compounds or developing novel methods to circumvent existing claims, especially in a highly crowded patent space like EGFR inhibitors.
8. Key Takeaways
- Scope: U.S. Patent 9,604,901 protects specific quinazoline derivatives targeting mutant EGFR, particularly relevant in NSCLC therapy.
- Claims: Focus on compound structure, synthesis, and therapeutic method claims, with narrow chemical coverage but strategic application.
- Patent Landscape: The field is highly competitive, with broad patents from AstraZeneca and Pfizer; the 9,604,901 patent adds a specific chemical niche.
- Strategic Position: The patent provides enforceable rights within its scope, supporting combination therapies or derivative compound development.
- Risk Management: Stakeholders should evaluate prior art, patent validity, and potential for design-around strategies.
References
[1] United States Patent and Trademark Office. US 9,604,901.
[2] Li, J., et al. Recent Advances in EGFR-Targeted Therapies in NSCLC. J Med Chem. 2018 Jan 25;61(2): 256–270.
[3] European Patent Office. Search on quinazoline derivatives patent families.
[4] Novartis AG. Clinical trials database.
Note: This analysis is current as of the knowledge cutoff date in 2023. Stakeholders should confirm ongoing patent statuses and consult legal counsel.
More… ↓
⤷ Start Trial
|
